Roche applies to EMA and FDA for shorter Ocrevus infusions
Roche aims to reduce the infusion time of its treatment for multiple sclerosis from 3.5 to 2 hours.
Archives for April 21, 2020
Regeneron’s Ebola treatment given US priority review
Regeneron’s triple antibody treatment for the Ebola virus has been provided US FDA priority review to speed regulatory action.
LNC Therapeutics acquires rights to develop Christensenella-based therapy for mood disorders
French biotech firm LNC Therapeutics is to enter into a licence agreement with the University of Valencia for a patent outlining the Christensenella gut bacteria's role in addressing mood disorders.